We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Benefits of Ultrasound Contrast Agents Supersede Potential Risk to Heart Patients

By MedImaging staff writers
Posted on 28 Apr 2008
A cardiologist called upon U.S. officials to reconsider a strong warning they recently placed on a diagnostic imaging modality, stating that the warning could prevent clinicians from detecting life-threatening cardiac events.

In October 2007, the U.S. Food and Drug Administration (FDA; Rockville, MD, USA) placed a black box warning on ultrasound contrast agents, which are used to improve the quality of echocardiography images in patients who do not otherwise have optimal images, after receiving reports of four deaths and serious reactions shortly after or during the infusion.

A black box warning is given to drugs that carry a considerable risk of serious or even life-threatening adverse effects. The warning placed on ultrasound contrast agents was issued without a formal examination of the risks and benefits of using them, reported Melda Dolan, M.D., associate professor of cardiology at Saint Louis University School of Medicine (MO, USA). Dr. Dolan's research demonstrated that the contrast agents are indeed safe, and withholding their use, which has occurred since the FDA warning, would make diagnosis of life-threatening heart disease more difficult.

"Based on the results of our study, we believe the FDA should reconsider its stance on contrast agents because the benefits outweigh the potential, although not established, risk,” stated Dr. Dolan, who was the lead investigator of the study. Dr. Dolan presented the research findings on March 31, 2008, at the 57th annual American College of Cardiology Scientific Session in Chicago, IL, USA.

In 1997, after significant scrutiny, the FDA approved the use of ultrasound contrast agents, which are gas-filled microbubbles that are administered intravenously into the blood, for these cases. The use of contrast agents to get optimal images is necessary in approximately one out of five individuals, according to Arthur Labovitz, M.D., director of the division of cardiology at Saint Louis University and a contributing researcher to the project.

The goal of this study was to assess the overall risk and benefits of ultrasound contrast agents. Utilizing findings from two university hospitals, the researchers examined the clinical outcomes of nearly 24,000 patients who received contrast agents during an echocardiogram and compared their results to those from a group of about 6000 patients who did not need to receive contrast agents.

To test the safety of contrast agents, the researchers looked at the short-term (within 30 minutes of the infusion) and long-term (within 24 hours) outcomes and noted any serious adverse events or deaths. Of the nearly 24,000 individuals to receive the contrast agents, not one experienced an adverse event within 30 minutes. One death and three non-fatal heart attacks occurred within 24 hours; however, these could not be attributed to the contrast agents.

To evaluate the effectiveness of ultrasound contrast agents, the researchers compared echocardiogram images, which were enhanced by contrast agents, with images of patients who did not need contrast agents. They found the images of both equally clear. The researchers evaluated the long-term survival rate of patients who received contrast agents during pharmaceutical stress echocardiogram exams and those who did not. They found nearly identical rates of death between both groups.


Related Links:
Food and Drug Administration
Saint Louis University School of Medicine
Ultrasonic Pocket Doppler
SD1
New
Mammography System (Analog)
MAM VENUS
Portable X-ray Unit
AJEX140H
Portable Color Doppler Ultrasound System
S5000

Channels

Nuclear Medicine

view channel
Image: The diagnostic tool could improve diagnosis and treatment decisions for patients with chronic lung infections (Photo courtesy of SNMMI)

Novel Bacteria-Specific PET Imaging Approach Detects Hard-To-Diagnose Lung Infections

Mycobacteroides abscessus is a rapidly growing mycobacteria that primarily affects immunocompromised patients and those with underlying lung diseases, such as cystic fibrosis or chronic obstructive pulmonary... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.